New constructive ivermectin evidence

A Pilot, Randomised, Placebo-Controlled, Double-Blind Trial of a Single Oral Dose of Ivermectin for Post-Exposure Prophylaxis of SARS-CoV-2 https://www.mdpi.com/1999-4923/17/9/1205 People who took one small oral dose of ivermectin after exposure, took longer to test positive and had more time alive and free of symptoms. Multiple reports from in vitro infectious models document Ivermectin’s antiviral properties https://pmc.ncbi.nlm.nih.gov/articles/PMC7564151/pdf/cells-09-02100.pdf Ivermectin has broad-spectrum antiviral activity. Randomised, double-blind, placebo-controlled Single oral dose of Ivermectin as prophylaxis for SARS-CoV-2 Trial to evaluate the effectiveness of a single oral low dose of Ivermectin Ability to prevent SARS-CoV-2 infection? Ability to reduce symptoms if infection did occur? Methods Asymptomatic community-dwelling adults Enrolled within 72 h of close contact with a case of SARS-CoV-2. Single oral 200 µg/kg dose of Ivermectin or placebo. 65Kg woman given 13mg 80Kg man given 16mg The primary outcome Conversion to a positive PCR or RAT test within 14 days of close contact. Secondary outcomes (for those who tested positive) Days alive free of symptoms in the 14 and 28 days following ivermectin Days from close contact until a positive PCR or RAT Results N = 536 (86 met inclusion criteria and were randomised) 68 adhered and were included in the analysis. Ivermectin arm 11/36 tested positive Placebo arm 11/32 tested positive So, ivermectin did not prevent people testing positive Days from close contact until a positive PCR or RAT Increased by 2.3 days in ivermectin group. P = 0.033 So, ivermectin lengthened the incubation period Viral load needed to precipitate clinical disease took longer to develop – indicating an antiviral effect. Infection may have been prevented from primary contact, - indicating an antiviral effect. Days alive free of symptoms Increased by 2.5 days in ivermectin group. P = 0.036 So ivermectin delayed onset of symptoms in people who tested positive (Longer asymptomatic period) Controlling included Age, prior SARS-CoV-2 infection, body mass index, hypertension, lung disease Conclusions We did not demonstrate that a single oral low dose of Ivermectin administered to asymptomatic adults within 72 h of close contact with a case of SARS-CoV-2 prevents conversion to a positive PCR or RAT. (may have done with a larger sample size) Amongst those who did convert to a positive PCR or RAT Ivermectin significantly lengthened the time from close contact to conversion Ivermectin increased the number of days alive free of symptoms More details Initiation of this trial in late 2021 Discovery in 1975 Massively used around the world Nobel Prize in 2015 Very low incidence of serious adverse side effects No instance of resistance reported in over 25 years. Ivermectin can bind to and inhibit the nuclear transport roles of the host importin α (IMPα) protein, which is known to mediate the nuclear import of various viral proteins and key host factors. Other quite distinct antiviral actions of Ivermectin have been proposed High (therapeutic) concentrations collect in the lungs, stable for more than 30 days in cattle Trial was based on the strong clinical retrospective association of statistically significantly lower mortality in patients who received oral Ivermectin (200 μg/kg) compared with usual care https://www.sciencedirect.com/science/article/pii/S0012369220348984 Ivermectin patients 15% mortality Controls, 25.2% mortality In subjects with severe pulmonary disease Ivermectin patients, mortality 38.8% Controls, 80.7% mortality Learn more about your ad choices. Visit megaphone.fm/adchoices